SCHEMBL6817833

SCHEMBL6817833

CCCCNc1nc(Cl)nc2c1ncn2C(C)C

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 3/20 0.63
CCNB2 O95067 1/20 0.62
CCNB1 P14635 1/20 0.62
CCNB3 Q8WWL7 1/20 0.62
CDK5 Q00535 11/20 0.57
CDK5R1 Q15078 10/20 0.57
CCNA2 P20248 9/20 0.57
CDK2 P24941 9/20 0.57
CCNA1 P78396 9/20 0.57
DYRK1A Q13627 7/20 0.57
HDAC1 Q13547 4/20 0.52
HDAC2 Q92769 4/20 0.52
NPC1 O15118 1/20 0.51
POLB P06746 1/20 0.51
HDAC8 Q9BY41 2/20 0.50
CCNK O75909 2/20 0.48
CDK12 Q9NYV4 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24966176 0.87 CDK1 (0.69) CDK1CCNB2CCNB1CCNB3CDK5
SCHEMBL5196519 0.83 CDK1 (0.55) CDK1CCNB2CCNB1CCNB3CDK5
SCHEMBL7094919 0.81 CDK1 (0.60) CDK1CDK5CDK5R1CCNA2CDK2
SCHEMBL17628610 0.81 CDK1 (0.79) CDK1CCNB2CCNB1CCNB3CDK5
SCHEMBL6817839 0.81 HDAC1 (0.67) HDAC1HDAC2HDAC8
SCHEMBL5196618 0.81 CDK1 (0.52) CDK1CCNB2CCNB1CCNB3CDK5
SCHEMBL22131204 0.79 CDK5 (0.65) CDK1CDK5CDK5R1CCNA2CDK2
SCHEMBL2318905 0.79 CDK1 (0.62) CDK1CCNB2CCNB1CCNB3CDK5
SCHEMBL6821041 0.79 CDK1 (0.62) CDK1CDK5CDK5R1CCNA2CDK2
SCHEMBL6152647 0.78 CDK1 (0.82) CDK1CCNB2CCNB1CCNB3CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1056745-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2004-06-16 EP disclosed
US-6413974-B1 INHIBITORS OF CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; PREVENTING APOPTOSIS IN NEURONAL CELLS; ANTINEOPLASTIC AGENTS; NEURONAL INJURY AND DEGENERATION; CEREBROVASCULAR DISEASE AVENTIS PHARMACEUTICALS INC. 2002-07-02 US disclosed
EP-1056745-A2 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES Aventis Pharmaceuticals Inc. (US) 2000-12-06 EP disclosed
WO-1999043676-A2 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMACEUTICALS INC. (US) 1999-09-02 WO disclosed